side effects of microdosing glp 1 GLP-1 There isn't enough data to

Nagashima M, Watanabe T, Terasaki M, Tomoyasu M, Nohtomi K, Kim-Kaneyama J, Miyazaki A, Hirano T: Native incretins prevent the development of atherosclerotic lesions in apolipoprotein E knockout mice

36: e14839

But we dont know if losing that weight, after perhaps decades of being overweight or obese, causes the chronic conditions that are associated with obesity to fully go away or lessen

Contrastingly, GLP1 antagonist sales in 2023 showcase a more diversified landscape, with therapeutics such as Ozempic, Trulicity, and Mounjaro driving 71 per cent of the sales. Looking ahead, the GLP1 agonist market is poised for robust growth, anticipating a 19.2 per cent compound annual growth rate (CAGR) from 2023 to 2029, reaching a substantial market size of $105 billion in 2029

PubMed CrossRef Carmellini P, Cuomo A, Rescalli MB, et al

If weight climbs after stopping, going back on the medication is a management decision, not a defeat